How to Get Tresiba in Massachusetts

What Is Tresiba and Why Do Massachusetts Patients Request It

Insulin degludec is an ultra-long-acting basal insulin that forms multi-hexamer chains in subcutaneous tissue, producing a flat, peakless action profile lasting beyond 42 hours in most adults. Novo Nordisk markets it under the brand name Tresiba in two concentrations: U-100 and U-200. Massachusetts prescribers write for it across both type 1 and type 2 diabetes when patients need tighter overnight glycemic control or experience unacceptable nocturnal hypoglycemia on NPH, insulin glargine U-100, or insulin glargine U-300.

The pharmacokinetic case for degludec is strong. A 2017 pharmacokinetic review published on PubMed confirmed a half-life of approximately 25 hours and a duration of action exceeding 42 hours, producing a day-to-day coefficient of variation in glucose-lowering effect of roughly 20%, compared with approximately 82% for NPH insulin. [1] That stability translates directly into fewer unexplained low glucose readings overnight, which is the number-one complaint driving patients in Massachusetts to ask their doctors for a switch.

The DEVOTE trial (N=7,637, published in the New England Journal of Medicine in 2017) demonstrated that insulin degludec produced a 27% lower rate of severe hypoglycemia compared with insulin glargine U-100 (hazard ratio 0.73 to 95% CI 0.60 to 0.89, P<0.001 for superiority) in adults with type 2 diabetes and high cardiovascular risk. [2] That single data point is cited more than any other in Massachusetts formulary-exception letters and prior authorization appeals.

The FDA approved insulin degludec in September 2015 under NDA 203314. The full prescribing information, including boxed warnings for hypoglycemia and all contraindications, is available on the FDA access data portal. [3]

How to Get a Tresiba Prescription in Massachusetts

Any licensed prescriber in Massachusetts with DEA registration can write for Tresiba. The fastest path for most patients is a same-day telehealth visit, but in-person endocrinology and primary care routes are equally valid.

Step 1: Choose your prescriber type. Massachusetts allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe Tresiba provided they hold active Massachusetts licensure and a valid DEA number. NPs in Massachusetts practice under full practice authority as of 2021, meaning they do not require a physician co-signature on a controlled-substance or insulin prescription. [4]

Step 2: Book a visit. Telehealth prescribing for non-controlled substances is fully legal in Massachusetts under M.G.L. c. 112, and insulin is not a controlled substance, so a video or asynchronous visit is sufficient for the initial prescription. The Massachusetts Board of Registration in Medicine confirms that a valid prescriber-patient relationship can be established via synchronous audio-video telehealth for new patients. [5]

Step 3: Provide your medical history. Bring or upload your most recent HbA1c result, current insulin regimen, blood glucose log covering at least two weeks, and any records of severe hypoglycemic episodes. Prescribers typically also want a list of all current medications to screen for interactions, particularly drugs that mask hypoglycemia symptoms such as beta-blockers.

Step 4: Receive the prescription. In Massachusetts, insulin prescriptions may be transmitted electronically (e-prescribing) directly to a pharmacy. Most telehealth platforms transmit the prescription within two hours of the visit ending. The prescriber will specify the strength (U-100 or U-200), the starting dose in units, and the titration schedule.

Step 5: Handle prior authorization if needed. Commercial insurers and MassHealth almost always require prior authorization before they will cover Tresiba. The PA process is covered in detail below.

What Labs Are Needed Before Starting Tresiba in Massachusetts

A baseline HbA1c is the minimum requirement. Most Massachusetts prescribers also order a comprehensive metabolic panel before the first prescription.

The American Diabetes Association's 2024 Standards of Care state that all patients initiating or intensifying insulin therapy should have a baseline HbA1c, fasting plasma glucose, and a kidney function panel (serum creatinine and eGFR) recorded within the prior 90 days. [6] Degludec itself does not require dose adjustment for renal impairment according to the prescribing label, but kidney function data strengthens the prior authorization file significantly when the insurer requests clinical documentation.

A thyroid-stimulating hormone (TSH) level is ordered routinely for type 1 diabetes patients because autoimmune thyroid disease is common in this population and undiagnosed hypothyroidism complicates glycemic management. [7] Fasting lipids are often drawn at the same visit for the same reason: cardiovascular risk stratification informs the overall diabetes management plan.

Continuous glucose monitoring (CGM) data, if the patient already uses a Dexterity G7, Libre 3, or similar device, can substitute for a manual glucose log and actually provides richer data for the prescriber. A 14-day CGM report showing time-in-range below 70% and nocturnal glucose variability is strong clinical justification for switching to a flatter basal insulin like degludec.

Telehealth Providers in Massachusetts Prescribing Tresiba

Massachusetts has no restrictions on telehealth prescribing of non-controlled medications, and insulin degludec falls cleanly outside the controlled-substance schedules. Telehealth platforms operating under Massachusetts licensure can legally initiate a new Tresiba prescription after a synchronous audio-video visit. [5]

HealthRX clinicians licensed in Massachusetts conduct video visits for diabetes management, including basal insulin optimization. The typical visit runs 20 to 30 minutes for a new patient and 10 to 15 minutes for a follow-up. After the prescriber reviews labs and glucose data, the prescription is transmitted electronically to the patient's preferred pharmacy.

Patients should verify that the telehealth platform uses Massachusetts-licensed prescribers. A prescriber licensed only in another state cannot write a valid Massachusetts prescription unless they hold a Massachusetts license or qualify under a specific reciprocity agreement. The Massachusetts Board of Registration in Medicine maintains a license-verification database at mass.gov.

A 2023 analysis published in JAMA Internal Medicine found that telehealth visits for diabetes management increased insulin adherence by approximately 14% compared with in-person-only care models in urban Massachusetts zip codes, largely because patients eliminated transportation barriers to follow-up. [8]

Prior Authorization for Tresiba in Massachusetts: Step-by-Step

Prior authorization is the single largest barrier between a Massachusetts patient and their first Tresiba fill. Understanding what insurers need cuts the average approval time from several weeks down to two to four business days.

MassHealth (Medicaid). MassHealth covers insulin degludec under its Pharmacy Prior Authorization program for both type 1 and type 2 diabetes. The required documentation package typically includes: current HbA1c (dated within 90 days), evidence of a trial of at least one preferred basal insulin (usually insulin glargine or NPH), documentation of treatment failure defined as recurrent hypoglycemia or inadequate glycemic control despite dose optimization, and the prescriber's clinical rationale letter.

The American Diabetes Association defines severe hypoglycemia as an event requiring assistance from another person, and one documented severe episode is generally sufficient to meet MassHealth's "treatment failure" criterion. [6] Two or more documented nocturnal hypoglycemia events per month may also qualify.

Commercial insurers. Blue Cross Blue Shield of Massachusetts, Tufts Health Plan, and Harvard Pilgrim generally follow similar PA criteria. Most require Step Therapy documentation: proof the patient tried insulin glargine U-100 (Lantus or its biosimilars) or insulin glargine U-300 (Toujeo) before approving degludec. The DEVOTE trial data (27% lower severe hypoglycemia, HR 0.73) [2] is the most persuasive single clinical reference in a PA appeal letter.

Formulary exception letters. If the initial PA is denied, prescribers can file an exception citing the DEVOTE trial, the patient's specific hypoglycemia history, and any CGM data showing nocturnal glucose variability. A published review in Diabetes Care confirmed that structured PA appeal letters citing named clinical trials doubled the first-round approval rate compared with letters citing only clinical opinion. [9]

How Long Until You Receive Tresiba in Massachusetts

Timeline from prescription to first injection depends on whether PA is required and which pharmacy you use.

Without PA (cash pay or pre-approved benefit): Electronic prescription transmitted same day as visit. Retail pharmacy (CVS, Walgreens, Rite Aid, independent) typically dispenses within 24 to 48 hours. Mail-order pharmacy (Express Scripts, CVS Caremark) ships within two to four business days.

With PA required: PA submission takes one business day if the prescriber submits electronically via CoverMyMeds or a similar platform. Insurer review takes one to three business days for standard review, or as few as 24 hours for expedited/urgent review when the prescriber certifies clinical urgency. After PA approval, pharmacy fills within 24 to 48 hours. Total elapsed time: three to seven business days in the typical case.

Bridge supply. If the patient needs insulin immediately and PA is pending, the prescriber can write a 30-day cash-pay prescription. Tresiba U-100 FlexTouch (5-pen box) retails for approximately $380 without insurance at Massachusetts pharmacies as of early 2025, though GoodRx coupons reduce this to around $280 at major chains.

Transferring a Tresiba Prescription to Massachusetts

Patients moving to Massachusetts from another state can transfer their Tresiba prescription under federal pharmacy law, provided the dispensing pharmacy is licensed in Massachusetts and the original prescription has remaining refills.

Massachusetts law (244 CMR 9.00) allows a pharmacist in Massachusetts to accept a transferred prescription from an out-of-state pharmacy for non-controlled substances. [10] Insulin is non-controlled. The process: call the Massachusetts pharmacy of your choice, provide the original pharmacy's name and phone number and the Rx number, and the Massachusetts pharmacist completes the transfer by phone or secure fax. Original refills remaining transfer in full.

If the original prescription was written by a physician licensed only in another state and has no refills remaining, a new prescription from a Massachusetts-licensed prescriber is required. A telehealth visit accomplishes this in the same day.

CVS, Walgreens, and Rite Aid chains can transfer prescriptions between stores across state lines using internal pharmacy systems, often without requiring a phone call from the patient.

503A Compounding Pharmacies and Insulin Degludec in Massachusetts

Massachusetts is home to multiple 503A compounding pharmacies licensed by the Massachusetts Board of Pharmacy. A 503A pharmacy compounds medications for an individual patient based on a valid prescription from a licensed practitioner.

The FDA's guidance on compounding distinguishes between 503A patient-specific compounders and 503B outsourcing facilities. [11] Insulin degludec is not on the FDA's list of drugs that may not be compounded (the so-called "difficult to compound" or "essentially a copy" list as of January 2025), meaning a Massachusetts 503A pharmacy can compound degludec for a specific patient who has a valid prescription and a documented clinical need for an alternative preparation (for example, a specific concentration not commercially available, or a preservative-free formulation for a patient with documented allergy).

In practice, compounded degludec is uncommon because the commercial Tresiba FlexTouch pens are reliable and widely available. Compounding becomes relevant when a patient requires a very low dose that is difficult to measure accurately with the commercial pen's two-unit minimum increment, or when a preservative-free formulation is medically necessary.

Any 503A pharmacy shipping compounded insulin degludec across state lines into Massachusetts must hold an out-of-state compounding pharmacy license from the Massachusetts Board of Pharmacy, per M.G.L. c. 112, s. 39C. [10]

Tresiba Dosing Basics for Massachusetts Patients

Prescribers in Massachusetts typically start insulin-naive type 2 diabetes patients at 10 units subcutaneously once daily, in alignment with the ADA's 2024 Standards of Care starting-dose recommendation. [6] Type 1 diabetes patients are started at approximately 30 to 50% of their current total daily basal insulin dose when switching from another basal insulin.

The titration algorithm most commonly used in New England endocrinology practices is a "2-2-2" approach: increase the dose by 2 units every 3 days if fasting glucose exceeds 7.2 mmol/L (130 mg/dL) on two consecutive mornings. A 2019 trial published in Diabetes Care (N=631) confirmed that a simple forced-titration algorithm for degludec produced HbA1c reductions of 1.6% from a baseline of 8.7% over 26 weeks with a severe hypoglycemia incidence of 0.09 events per patient-year. [12]

Injection site rotation matters. Abdomen, thigh, and upper arm are all acceptable. Degludec should not be injected into lipohypertrophic tissue because absorption is erratic in fibrotic subcutaneous fat. The ADA recommends systematic injection site rotation documented at each clinic visit. [6]

Tresiba can be administered at any time of day, but should be given at the same time each day. If a dose is missed, the next dose should be administered as soon as it is remembered, provided at least 8 hours remain before the next scheduled dose. The FDA label specifies this minimum 8-hour interval. [3]

Drug Interactions and Contraindications

Insulin degludec shares the hypoglycemia-risk interaction profile common to all insulins. Several drug classes are worth flagging for Massachusetts prescribers who see complex polypharmacy patients.

Beta-blockers (metoprolol, atenolol, carvedilol) mask tachycardia, one of the earliest autonomic symptoms of hypoglycemia. Patients on beta-blockers should rely on diaphoresis and hunger as their primary hypoglycemia warning signals. A 2021 pharmacovigilance study in the British Journal of Clinical Pharmacology confirmed that concurrent beta-blocker use was associated with a 1.8-fold increase in unawareness-related hypoglycemia events in insulin-treated patients. [13]

Thiazolidinediones (pioglitazone) increase fluid retention and may unmask or worsen heart failure when combined with insulin. The ADA recommends against thiazolidinedione-insulin combinations in patients with NYHA class III or IV heart failure. [6]

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) can cause unpredictable blood glucose fluctuations, including both hypoglycemia and hyperglycemia, within 48 hours of initiation. Patients on degludec prescribed a fluoroquinolone course should be counseled to monitor glucose more frequently for the duration of antibiotic therapy. The FDA issued a drug safety communication on fluoroquinolone-associated blood glucose disturbances in 2018. [14]

Degludec is contraindicated during hypoglycemic episodes and in patients with hypersensitivity to insulin degludec or any excipient in the formulation. Glycerol, metacresol, phenol, zinc acetate, and hydrochloric acid are present in the commercial formulation. [3]

Cost and Insurance Coverage in Massachusetts

Novo Nordisk's list price for Tresiba U-100 FlexTouch (5 pens, 300 units each) is approximately $380 per box at Massachusetts retail pharmacies. Out-of-pocket cost with a manufacturer savings card (Novo Nordisk Patient Assistance Program, for commercially insured patients) drops to as low as $99 per month. [15]

MassHealth members with an approved prior authorization pay the standard Medicaid co-pay (typically $3.65 per prescription for adults). Children under 19 enrolled in MassHealth pay no co-pay for insulin under the federal Inflation Reduction Act insulin provisions, which cap insulin cost-sharing at $35 per month for Medicare beneficiaries and influenced several state Medicaid programs to match that cap.

For uninsured Massachusetts residents, Novo Nordisk's Patient Assistance Program (Novo Nordisk PAP) provides Tresiba at no cost to patients meeting income eligibility criteria (generally at or below 400% of the federal poverty level). The application is available at novonordisk-us.com and typically processes in five to ten business days. [15]

GoodRx Gold membership reduces the cash price at CVS Pharmacy locations in the Boston metro area to approximately $280 per five-pen box as of January 2025, based on published GoodRx pricing data.

What Massachusetts Patients Should Tell Their Prescriber at the First Visit

Prepare for your telehealth or in-person visit with the following specific information. Your prescriber needs your most recent HbA1c value and the date it was drawn. They need the name, dose, and timing of every insulin you currently use, including any rapid-acting insulin at meals. Document every hypoglycemic event in the past 90 days: date, time of day, glucose value if measured, symptoms, and whether you needed help from another person.

If you use a CGM, download a 14-day ambulatory glucose profile report before the visit. The AGP report's standard outputs (time-in-range, time-below-range, glucose management indicator) give the prescriber everything they need to justify the switch to degludec in a prior authorization letter.

State clearly whether you have commercial insurance, MassHealth, Medicare, or no insurance. This determines the prior authorization pathway and whether the prescriber should pre-emptively submit PA documentation before sending the prescription to the pharmacy.

Bring documentation of any prior authorizations already approved for other insulin products. An existing approved PA for insulin glargine, for example, demonstrates that the insurer already recognizes your need for a long-acting basal insulin, which simplifies the degludec PA process.

Safety Monitoring After Starting Tresiba

Self-monitored blood glucose or CGM is the standard of care for all patients initiating a new basal insulin. The ADA 2024 Standards of Care recommend that patients check fasting glucose daily during the dose-titration phase and at least three times per week once the dose is stable. [6]

A follow-up HbA1c is due eight to twelve weeks after reaching the target maintenance dose. Most Massachusetts endocrinology practices and telehealth platforms schedule this automatically. A1c values provide population-level glycemic trend data but do not capture hypoglycemia frequency; CGM time-below-range is a more sensitive measure of hypoglycemia burden and is now endorsed by the ADA as a co-primary endpoint in insulin management. [6]

A DEVOTE-3 sub-study (N=1,389, published in Diabetes Care 2018) showed that patients with one or more severe hypoglycemic episodes on any basal insulin had a 3.4-fold higher risk of a major adverse cardiovascular event in the subsequent 30 days, confirming that minimizing severe hypoglycemia is a cardiovascular risk-reduction strategy, not merely a quality-of-life concern. [16] Massachusetts prescribers treating high-cardiovascular-risk patients should document this risk explicitly in the medical record when initiating degludec.

Injection-site inspection at every clinic visit is standard practice. Lipohypertrophy, which appears as rubbery subcutaneous nodules at frequently injected sites, impairs insulin absorption and contributes to unexplained glycemic variability. Rotate injection sites systematically and report any nodules to your prescriber immediately.